The DOI matches its Crossref record.
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors
Open accessAbstract
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTNon-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitorsGeorge D. Hartman, Melissa S. Egbertson, Wasyl Halczenko, William L. Laswell, Mark E. Duggan, Robert L. Smith, Adel M. Naylor, Patricia D. Manno, Robert J. Lynch, and Cite this: J. Med. Chem. 1992, 35, 24, 4640–4642Publication Date (Print):November 1, 1992Publication History Published online1 May 2002Published inissue 1 November 1992https://pubs.acs.org/doi/10.1021/jm00102a020https://doi.org/10.1021/jm00102a020research-articleACS PublicationsRequest reuse permissionsArticle Views1233Altmetric-Citations247LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Computational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Therapeutic potential of venom peptides
Lewis, R. J., & Garcia, M. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1197 · Cited by 798
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Kapp, T. G., Rechenmacher, F., Neubauer, S., Maltsev, O. V., Cavalcanti-Adam, E. A., Zarka, R., Reuning, U., Notni, J., Wester, H.-J., Mas-Moruno, C., et al. (2017) · Scientific Reports · doi:10.1038/srep39805 · Cited by 620
Protein structure-based drug design: from docking to molecular dynamics
Śledź, P., & Caflisch, A. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.10.010 · Cited by 565
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Metallaphotoredox-catalysed sp3–sp3 cross-coupling of carboxylic acids with alkyl halides
Johnston, C. P., Smith, R. T., Allmendinger, S., & MacMillan, D. W. C. (2016) · Nature · doi:10.1038/nature19056 · Cited by 469
Self-citationComputer Aided Drug Design: Success and Limitations
Hassan Baig, M., Ahmad, K., Roy, S., Mohammad Ashraf, J., Adil, M., Haris Siddiqui, M., Khan, S., Amjad Kamal, M., Provazník, I., & Choi, I. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151125000550 · Cited by 424
Comparison of Topological, Shape, and Docking Methods in Virtual Screening
McGaughey, G. B., Sheridan, R. P., Bayly, C. I., Culberson, J. C., Kreatsoulas, C., Lindsley, S., Maiorov, V., Truchon, J.-F., & Cornell, W. D. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci700052x · Cited by 417
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · Chest · doi:10.1378/chest.11-2293 · Cited by 379
Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting
Huang, J., Li, X., Shi, X., Zhu, M., Wang, J., Huang, S., Huang, X., Wang, H., Li, L., Deng, H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0709-6 · Cited by 377
Integrins as therapeutic targets
Goodman, S. L., & Picard, M. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.002 · Cited by 376
Molecular Shape and Medicinal Chemistry: A Perspective
Nicholls, A., McGaughey, G. B., Sheridan, R. P., Good, A. C., Warren, G., Mathieu, M., Muchmore, S. W., Brown, S. P., Grant, J. A., Haigh, J. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900818s · Cited by 310
Bordon, K. D. C. F., Cologna, C. T., Fornari-Baldo, E. C., Pinheiro-Júnior, E. L., Cerni, F. A., Amorim, F. G., Anjolette, F. A. P., Cordeiro, F. A., Wiezel, G. A., Cardoso, I. A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01132 · Cited by 303
The chemistry of snake venom and its medicinal potential
Oliveira, A. L., Viegas, M. F., da Silva, S. L., Soares, A. M., Ramos, M. J., & Fernandes, P. A. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00393-7 · Cited by 289
Ran, X., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 263
Metadata
- Authors
- Hartman, G. D., Egbertson, M. S., Halczenko, W., Laswell, W. L., Duggan, M. E., Smith, R. L., Naylor, A. M., Manno, P. D., & Lynch, R. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1992-11
- Volume
- 35
- Issue
- 24
- Pages
- 4640-4642
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2008235594
- Cited by
- 301
- References
- 0
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.